Diagnostics (Basel, Switzerland)Jul 15, 2026

Tracking Bone Loss During GLP-1RA Treatment Using a Urine Test for Bone Breakdown

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗OA ↗

Updated Jul 16, 2026

Abstract

Dual-agonist therapies may confer a relatively higher risk of osteoporosis and fractures compared to GLP-1RA monotherapy.

GLP-1RA monotherapy appears to have modest or no adverse effects on bone mineral density.
Increased weight loss and reductions in lean body mass could mediate the higher osteoporosis risk associated with dual agonists.
Older adults and postmenopausal women with low baseline bone mineral density may be particularly susceptible to increased fracture risk under rapid weight loss conditions.
Pre-existing osteopenia and nutritional deficiencies may further amplify the risk of osteoporosis.
Dynamic bone resorption markers, such as deoxypyridinoline, may provide more sensitive monitoring of bone health compared to traditional imaging methods.

Simplified

Skeletal safety of glucagon-like peptide-1 receptor agonists (GLP-1RAs) remains uncharted, with emerging evidence suggesting a divergence between mono- and dual-agonist therapies. GLP-1RA monotherapy appears bone-neutral, with modest or no adverse effects on bone mineral density (BMD), whilst dual agonists may confer a relatively higher risk of osteoporosis and fractures, plausibly mediated by greater weight loss magnitude and concomitant reductions in lean body mass (LBM) rather than direct osteotoxicity. Intensified surveillance is warranted in susceptible phenotypes, including older adults and postmenopausal women with low baseline BMD under conditions of rapid weight loss. Osteoporosis risk is further amplified by pre-existing osteopenia, nutritional deficiencies, and concomitant exposure to bone-active agents. Given the limitations of serial dual-energy X-ray absorptiometry (DXA), including cumulative radiation exposure and limited sensitivity to early remodeling changes, biochemical markers potentially depict bone turnover more dynamically. Measurement of dynamic bone resorption markers enables early identification of skeletal disturbances, supporting proactive adjustment of therapeutic strategy, dosing, and duration. Specifically, deoxypyridinoline (DPD), a bone-specific collagen crosslink, is a highly sensitive and rapidly responsive urine biomarker of osteoclastic activity. Incorporating DPD urine testing into monitoring frameworks potentially facilitates individualized therapeutic modulation, optimizing the metabolic efficacy of GLP-1RAs while safeguarding skeletal integrity.

Full Text

Full text is available at the source.

View Full Text ↗

Tracking Bone Loss During GLP-1RA Treatment Using a Urine Test for Bone Breakdown

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the glp-1 therapies brief

Abstract

Full Text

Related papers

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the glp-1 therapies brief